Name
Development and Evaluation of an Orally Available Prophylactic Medical Countermeasure for Acute Radiation Syndrome
Speakers
Content Presented on Behalf of
Other/Not Listed
Services/Agencies represented
Uniformed Services University (USU)
Session Type
Posters
Room#/Location
Prince Georges Exhibit Hall
Focus Areas/Topics
Trending/Hot Topics or Other not listed
Learning Outcomes
1) Discuss the DOD’s opportunity to improve their approach to prophylactic radiation MCMs and their development under the FDA Animal Rule.
2) Describe the nonclinical and clinical data supporting BIO 300 as an orally available prophylactic radiation MCM.
3) Describe the pharmacodynamic data that will be used for human dose selection for BIO 300 under the FDA Animal Rule.
2) Describe the nonclinical and clinical data supporting BIO 300 as an orally available prophylactic radiation MCM.
3) Describe the pharmacodynamic data that will be used for human dose selection for BIO 300 under the FDA Animal Rule.
Session Currently Live